Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients-Reference-Cited by-同舟云学术

Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients

Published:2022-01-17 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Heijden Charlotte D. C. C.¹^ORCID,Heine Rob²,Kooistra Emma J.³,Brüggemann Roger J.³^ORCID,Walburgh Schmidt Jesper W. J.²,Grouw Elke P. L. M.⁴,Frenzel Tim²,Pickkers Peter²,Leentjens Jenneke¹^ORCID

Affiliation:

1. Department of Internal Medicine, Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen the Netherlands

2. Department of Pharmacy, Radboud University Medical Center Radboud Institute for Health Sciences Nijmegen the Netherlands

3. Department of Intensive Care Radboud University Medical Center Nijmegen the Netherlands

4. Department of Clinical Chemistry Radboud University Medical Center the Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15208

Reference37 articles.

1. Incidence of venous thromboembolism in hospitalized patients with COVID‐19;Middeldorp S;J Thromb Haemost,2020

2. Clinical and computed tomography characteristics of COVID‐19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?;Dam LF;Thromb Res,2020

3. High risk of thrombosis in patients with severe SARS‐CoV‐2 infection: a multicenter prospective cohort study;Helms J;Intensive Care Med,2020

4. COVID‐19‐associated coagulopathy and antithrombotic agents‐lessons after 1 year;Leentjens J;Lancet Haematol,2021

5. ISTH DIC subcommittee communication on anticoagulation in COVID‐19;Thachil J;J Thromb Haemost,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19;Clinical Pharmacokinetics;2023-04-25

2. Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?;Clinical Pharmacokinetics;2022-12-30

3. Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients;British Journal of Clinical Pharmacology;2022-12-26